Do you want to read an article? Please log in or register.
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Inflammatory Bowel Disease
RECOMMENDED
Related content
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
RECOMMENDED
Inflammatory Bowel Disease
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1093/ecco-jcc/jjaa075.
Inflammatory Bowel Disease
Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
J Crohns Colitis.
Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW
doi: 10.1093/ecco-jcc/jjz042.
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.
Inflammatory Bowel Disease
Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy
J Crohns Colitis.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W
doi: 10.1093/ecco-jcc/jjz048.
Inflammatory Bowel Disease
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
J Crohns Colitis
Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-Cadilla J, Arroyo MT, Manceñido N, Sierra-Ausín M, Vera-Mendoza I, Casanova MJ, Nos P, González-Muñoza C, Martínez T, Boscá-Watts M, Calafat M, Busquets D, Girona E, Llaó J, Martín-Arranz MD, Piqueras M, Ramos L, Surís G, Bermejo F, Carbajo AY, Casas-Deza D, Fernández-Clotet A, García MJ, Ginard D, Gutiérrez-Casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-Ochoa O, Rancel FJ, Taxonera C, López Sanromán A, Rubio S, Domènech E, Gisbert JP
doi: 10.1093/ecco-jcc/jjaa145
Inflammatory Bowel Disease
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol.
Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML
doi: 10.1080/00365521.
Inflammatory Bowel Disease
Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
Inflamm Bowel Dis.
Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D
doi: 10.1093/ibd/izz204.
Inflammatory Bowel Disease
Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis
Inflamm Intest Dis.
Baehler C, Brüngger B, Blozik E, Vavricka SR, Schoepfer AM
doi: 10.1159/000502205.